Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

Conditions: Atopic Dermatitis (AD)

Sex: All

Ages: 12 Years – N/A

Healthy volunteers: No

Enrollment: 200

Sponsor: AbbVie

Location: Peking University Third Hospital /ID# 257722 Beijing Beijing Municipality

Summary

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants. Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice

Eligibility Criteria

Inclusion Criteria: * Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment. * Chinese adolescents (≥12 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05959083). StuddyBuddy aggregates publicly available trial information.